Dashboard
Manage Tickers

GNFTGenfit S.A.

Nasdaq genfit.com


$ 4.27 $ 0.24 (6.15 %)    

Tuesday, 27-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.16 $ -5.41 (-1.13 %)
DIA $ 411.36 $ -1.55 (-0.38 %)
SPY $ 558.32 $ -3.26 (-0.58 %)
TLT $ 97.88 $ -0.12 (-0.12 %)
GLD $ 231.76 $ -1.64 (-0.7 %)
$ 4.214
$ 4.15 x 200
$ 4.26 x 200
-- - --
$ 2.89 - $ 6.05
2,050
na
210M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-genfit-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Genf...
07/29/2024 10:13:00

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $13 price target.

fda-fast-tracks-ipsen-and-genfits-new-liver-disease-treatment-iqirvo
FDA Fast-Tracks Ipsen And Genfit's New Liv...
06/11/2024 13:18:23

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating prima...

hc-wainwright--co-maintains-buy-on-genfit-raises-price-target-to-13
HC Wainwright & Co. Maintains Buy on Genfi...
06/11/2024 12:43:18

HC Wainwright & Co. analyst Ed Arce maintains Genfit (NASDAQ:GNFT) with a Buy and raises the price target from $11 to $13.

trading-halt-halt-status-updated-at-55000-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 5:50:...
06/10/2024 21:50:04

Core News & Articles
GENFIT Says Iqirvo Is First-ever Drug Deve...
06/10/2024 21:26:27

GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S....

Core News & Articles
Ipsen Says Iqirvo Secured FDA Accelerated ...
06/10/2024 20:59:52

Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed f...

trading-halt-halted-at-44203-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:42:03 p.m. ET - ...
06/10/2024 20:42:07

hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Genf...
06/06/2024 10:34:43

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

why-sentinelone-shares-are-trading-lower-by-16-here-are-other-stocks-moving-in-fridays-mid-day-session
Why SentinelOne Shares Are Trading Lower B...
05/31/2024 17:17:02

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
05/31/2024 12:06:22

why-zscaler-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Zscaler Shares Are Trading Higher By A...
05/31/2024 11:44:15

hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Genf...
05/15/2024 14:45:40

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Genf...
04/05/2024 12:10:09

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

genfit-fy23-eps-062-down-from-049-yoy-sales-4109m-up-from-2712m-yoy
Genfit FY23 EPS $(0.62) Down From $(0.49) ...
04/04/2024 22:03:13

Genfit (NASDAQ:GNFT) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) pe...

genfit-fy23-eps-058-vs-048-yoy-revenue-38176-million-vs-26566-million-yoy
GENFIT FY23 EPS €(0.58) Vs €(0.48) YoY; Re...
04/04/2024 20:13:47

earnings-scheduled-for-april-4-2024
Earnings Scheduled For April 4, 2024
04/04/2024 09:18:17

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on r...

genfit-2023-revenues-286m-up-from-202m-yoy
GENFIT 2023 Revenues €28.6M, Up From €20.2...
02/29/2024 21:22:02

hc-wainwright--co-reiterates-buy-on-genfit-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Genf...
12/08/2023 14:39:50

HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.

Core News & Articles
Ipsen Confirms FDA Grants Priority Review ...
12/07/2023 10:17:25

Ipsen ((Euronext: IPN, OTC:IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administra...

genfit-announces-publication-in-the-journal-of-hepatology-on-the-accurate-performance-of-nis2-as-a-screening-tool-for-the-enrollment-of-patients-in-mash-clinical-trials
GENFIT Announces Publication In The Journa...
12/06/2023 16:34:29

The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failur...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION